Literature DB >> 15921157

Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-kappaB activity.

Hongen Yin1, Hong Cheng, Mengxue Yu, Fengchun Zhang, Jiayou Lin, Yang Gao, Bing Han, Liping Zhu.   

Abstract

The objectives of this work were to observe the multiple immuno-regulating effects of vasoactive intestinal peptide (VIP) on synovial cells of collagen induced arthritis (CIA) rats and to determine whether the transcriptional factor-kappaB (NF-kappaB) signal pathway was involved. CIA was induced using female Wistar rats by native bovine type II collagen (C II) emulsified with complete Freund's adjuvant (CFA). Synovial cells from the knees of the CIA rats were cultivated, and the effects of VIP and VIP receptor inhibitor ([D-P-Cl-Phe(6),Leu(17)]-VIP, I) on proliferation and apoptosis of the synovial cells were assayed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carcoxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), flow cytometry, and DNA integrity. The effects of VIP and [D-P-Cl-Phe(6), Leu(17)]-VIP on mRNA expression of several cytokines in the synovial cells including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), regulated upon activation, normal T-cell expressed and secreted (RANTES), inducible NO synthase (iNOS), matrix metalloproteinase-2 (MMP-2) and MMP-9 were estimated by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Effects of VIP and [D-P-Cl-Phe(6), Leu(17)]-VIP on NF-kappaB activity were analyzed using luciferase gene reporter assays. Effects of VIP and [D-P-Cl-Phe(6),Leu(17)]-VIP on p65NF-kappaB expression of the synovial cells were examined by Western blot. Seventy-five percent of the induced rats developed CIA. VIP has multiple effects on synovial cells of CIA rats including decreasing proliferation, inducing apoptosis, and down-regulating mRNA expression of several inflammatory factors. VIP was found to play immuno-regulating roles through the down-regulation of the activity and expression of NF-kappaB, whereas VIP receptor blockade was found to counteract all the effects. In conclusion, VIP was found to ameliorate synovial cell functions of CIA rats through binding with receptors and further down-regulating NF-kappaB signal pathway, suggesting VIP is a potential anti-inflammatory and anti-rheumatic agent of CIA by blocking NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921157

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  6 in total

1.  Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad.

Authors:  Francesco Vetrini; Nicola Brunetti-Pierri; Donna J Palmer; Terry Bertin; Nathan C Grove; Milton J Finegold; Philip Ng
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

Review 2.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 3.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  MicroRNA-26a reduces synovial inflammation and cartilage injury in osteoarthritis of knee joints through impairing the NF-κB signaling pathway.

Authors:  Zhi Zhao; Xiu-Song Dai; Zhi-Yan Wang; Zheng-Qi Bao; Jian-Zhong Guan
Journal:  Biosci Rep       Date:  2019-04-09       Impact factor: 3.976

Review 5.  An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.

Authors:  Rosa P Gomariz; Yasmina Juarranz; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; Isidoro González-Álvaro; Irene Gutiérrez-Cañas; Amalia Lamana; Carmen Martínez
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-22       Impact factor: 5.555

Review 6.  Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?

Authors:  Susanne Grässel; Dominique Muschter
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.